Home/Pipeline/SKY02

SKY02

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

SEEKYO Therapeutics

About SEEKYO Therapeutics

Seekyo Therapeutics, founded in 2018 and based in Paris, is pioneering a new paradigm in oncology with its Tumor Activated Therapy™ platform. This approach targets functional proteins selectively produced within the tumor microenvironment, enabling localized activation of therapeutic agents to overcome tumor heterogeneity and reduce systemic toxicity. The company's lead program, SKY01, has demonstrated efficacy and safety in animal models across multiple difficult-to-treat solid tumors, positioning Seekyo to address a significant unmet need in oncology. It operates as a private, preclinical-stage biotech seeking partnerships to advance its internal pipeline and platform.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed